Disease · MONDO_0008538
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Mavrilimumab vs Placebo: deaths from any cause | 0 of 42 | 0 of 28 | 70 | NCT03827018 | Trial comparisons |
| Mavrilimumab vs Placebo: serious adverse events | 2 of 42 | 3 of 28 | 70 | NCT03827018 | Trial comparisons |
| Main Study: Guselkumab vs Main Study: Placebo: Main Study: Number of Participants With Treatment-emergent Serious Adverse Event (SAEs) | 6 of 35 | 0 of 18 | 53 | NCT04633447 | Trial comparisons |
| Main Study: Guselkumab vs Main Study: Placebo: Main Study: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 34 of 35 | 17 of 18 | 53 | NCT04633447 | Trial comparisons |
| Secukinumab vs Placebo: Percentage of Participants With GCA Who Had Sustained Remission Until Week 52 | 16 of 27 | 2 of 25 | 52 | NCT03765788 | Trial comparisons |
| Secukinumab vs Placebo: Percentage of Participants in Remission at Week 12 | 22 of 27 | 12 of 25 | 52 | NCT03765788 | Trial comparisons |
| Secukinumab vs Placebo: Percentage of Participants in Sustained Remission Until Week 28 | 19 of 27 | 6 of 25 | 52 | NCT03765788 | Trial comparisons |
| TCZ IV 7 mg/kg Q4W vs TCZ IV 6 mg/kg Q4W: deaths from any cause | 0 of 24 | 0 of 22 | 46 | NCT03923738 | Trial comparisons |
| TCZ IV 7 mg/kg Q4W vs TCZ IV 6 mg/kg Q4W: serious adverse events | 3 of 24 | 1 of 22 | 46 | NCT03923738 | Trial comparisons |
| Tocilizumab vs Placebo: Number of Relapse Free Patients | 17 of 20 | 2 of 10 | 30 | NCT01450137 | Trial comparisons |
| Tocilizumab vs Placebo: Number of Patients That Have Achieved Complete Remission of Disease | 17 of 20 | 4 of 10 | 30 | NCT01450137 | Trial comparisons |
| Tocilizumab vs Placebo: deaths from any cause | 0 of 20 | 1 of 10 | 30 | NCT01450137 | Trial comparisons |
| Tocilizumab vs Placebo: serious adverse events | 7 of 20 | 5 of 10 | 30 | NCT01450137 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008538/comparisons